141 related articles for article (PubMed ID: 8610445)
1. Characterization of Epstein-Barr virus recombinants with deletions of the BamHI C promoter.
Swaminathan S
Virology; 1996 Mar; 217(2):532-41. PubMed ID: 8610445
[TBL] [Abstract][Full Text] [Related]
2. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
3. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
4. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
5. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus replicative gene transcription during de novo infection of human thymocytes: simultaneous early expression of BZLF-1 and its repressor RAZ.
Kelleher CA; Paterson RK; Dreyfus DH; Streib JE; Xu JW; Takase K; Jones JF; Gelfand EW
Virology; 1995 Apr; 208(2):685-95. PubMed ID: 7747440
[TBL] [Abstract][Full Text] [Related]
7. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
[TBL] [Abstract][Full Text] [Related]
8. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Puglielli MT; Woisetschlaeger M; Speck SH
J Virol; 1996 Sep; 70(9):5758-68. PubMed ID: 8709191
[TBL] [Abstract][Full Text] [Related]
9. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes.
McClain K; Estrov Z; Raju U; Kelley PK; Aggarwal BB
Methods; 1997 Jan; 11(1):83-7. PubMed ID: 8990093
[TBL] [Abstract][Full Text] [Related]
11. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
12. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV.
Yalamanchili R; Tong X; Grossman S; Johannsen E; Mosialos G; Kieff E
Virology; 1994 Nov; 204(2):634-41. PubMed ID: 7941331
[TBL] [Abstract][Full Text] [Related]
13. Transcription of Epstein-Barr virus latent cycle genes in oral hairy leukoplakia.
Webster-Cyriaque J; Raab-Traub N
Virology; 1998 Aug; 248(1):53-65. PubMed ID: 9705255
[TBL] [Abstract][Full Text] [Related]
14. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
16. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
17. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
Robertson ES; Tomkinson B; Kieff E
J Virol; 1994 Mar; 68(3):1449-58. PubMed ID: 8107208
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
19. Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.
Rooney CM; Brimmell M; Buschle M; Allan G; Farrell PJ; Kolman JL
J Virol; 1992 Jan; 66(1):496-504. PubMed ID: 1309259
[TBL] [Abstract][Full Text] [Related]
20. Characterization of natural Epstein-Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma.
Jenson HB; Montalvo EA; McClain KL; Ench Y; Heard P; Christy BA; Dewalt-Hagan PJ; Moyer MP
J Med Virol; 1999 Jan; 57(1):36-46. PubMed ID: 9890420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
